K-V Pharmaceutical Co. Opiniones

zokaira tu eres la que mas sabe a ca que dice cancun

el mercado esta comentando empesando a subir

pues aqui se baraja la opción de "nuevas acciones"

compradores a 0.21 y vendedores a 0.215 casi al cierre dice algo

ojo es una propuesta el juez no lo aprovo todavia me imagino que tendra que valorar el valor de la patente

RiacardP,dice Cancun q en el nuevo plano no se menciona la cancelacion de la acciones, y no mas W.Street Journal publico la news de la nueva propuesta de Silver Point los cortos se redujeron a minimos y llevaban el predominio de la sesion. Desde 20.52hrs aumento en volumen de compras aumentando el precio, evidentemente habia confusion entre los operadores, pero la news ha sido bien recibida pues se disparó la cotizacion. El vol, en cortos no obstante ha sido m.alto hoy 61.05% pero comenzó a decrecer partir de 20.30hrs,revisa esta pagina,
http://uk.advfn.com/p.php?pid=trades&symbol=NO%5eKVPHQ la columna q dice Sell es la de ventas en corto, y Sell vol,los colores rojo pertenecen a cortos. Esos son los q piensan q va a bajar y venden para recompar mas abajo. hoy sin dudas se han equivocado pero esperemos.
Mañana sera decisivo. ¿ Como tu interpretas la oferta de Silver Point.. ? Cancun aun no me la ha comentado, acaba de publicarla W.Street Jorunal a final de sesion. Si eso fue hoy a ultima hora mañana debe dispararse hasta cerca de 0.30.

Siempre habra nueva acciones, estan restructurando la cia por ejemplo las q se le canjean a tenedores de bonos no garantizados

Silver Point Offers to Sponsor Plan for K-V Pharmaceutical
Stephanie Gleason
June 03, 2013
(c) 2013 Dow Jones & Company, Inc.
Senior bondholder Silver Point Finance LLC has submitted a proposal letter for K-V Pharmaceutical Co . that matches an offer from a group of investors holding subordinate bonds.
The subsidiary of hedge fund Silver Point Capital LP announced Friday that it is "prepared to sponsor a chapter 11 plan that is identical to the structure of the Convert Plan, but indisputably provides more value to the Debtors' estates and creditors," according to documents filed with the U.S. Bankruptcy Court in Manhattan.
Silver Point said that its first offer was a better deal for K-V, but the pharmaceutical company was on the verge of moving forward with the convertible bondholder investor group, so it is willing to match that deal.
The new Silver Point offer lowers to $5 million the breakup fee that would be required if the deal isn't ultimately executed. It reduces to 4.5% the amount of common stock Silver Point would be entitled to as a fee and increases to $10.25 million the recovery for unsecured creditors.
A previous offer from the convertible group---which is composed of funds controlled by Greywolf Capital, Capital Venture International, Deutsche Bank Securities Inc . and Kingdon Associates---required a $7.5 million breakup fee, a 5% common stock fee and provided $10 million to unsecured creditors.
Silver Point would also sponsor a rights offering for $210 million and would directly purchase $65 million worth of K-V's new stock. The $210 million rights offering would last for three days, during which time convertible bondholders could purchase those shares, otherwise they revert to Silver Point.
The letter from Silver Point doesn't specifically lay out how much stock the direct purchase or the rights offering entitles it to. However, Silver Point called its proposal "identical" to the one offered by the convertible group.
The rights offering under that proposal was for $200 million---10 million shares at $20 per share. The group's proposed $75 million direct stock purchase gave them 24% equity. Together, the group potentially could have ended up with 88% equity in the new K-V if all the shares in the offering reverted to the group.
Valuing the shares, Silver Point would wind up with 20.8% equity for its $65 million and is offering 67.2% equity in the rights offering. It would also end up with an 88% stake if it got all the rights offering shares.
Silver Point is part of a group of senior bondholders and bankruptcy lenders, which also includes Whitebox Advisors LLC and Pioneer Investment Management, owed $225 million plus interest in bonds and $85 million in bankruptcy financing. Those bondholders were being paid in cash in full under the convertible group-sponsored plan.
Convertible bondholders, owed $200 million, are entitled to participate in the rights offering and receive 7% common stock under both plans.
K-V filed for Chapter 11 protection in August, embroiled in controversy over its preterm labor drug, Makena. The only drug with Food and Drug Administration approval to prevent preterm labor, Makena was expected to rake in profits for the company.
However, when K-V rolled out its pricing structure, $1,500 per injection, the medical community pushed back and didn't prescribe it, instead continuing to give patients a compounded version that cost far less.
The FDA declined to act to stop the cheaper versions from being produced by compounding pharmacies, and sales of Makena stayed low. Since then, sales of the drug have increased as compounding practices have come under scrutiny.
Write to Stephanie Gleason at [email protected].
To read more stories like this login at the top right or try the product

http://www.vectorvest.com/stockanalysis/stockanalysisuk.aspx?http_referer=&cr0=&cr1=